Genmab A/S (GMAB) Competitors

Takeda Pharmaceutical (NYSE:TAK) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.

Which has stronger valuation and earnings, TAK or GMAB?

Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.20B	1.51	$994.06M	$0.55	24.49
Genmab A/S	$17.78B	1.03	$631.91M	$1.20	23.14

Does the media refer more to TAK or GMAB?

In the previous week, Genmab A/S had 9 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 13 mentions for Genmab A/S and 4 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.75 beat Genmab A/S's score of 0.73 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, TAK or GMAB?

Takeda Pharmaceutical has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.

Does the MarketBeat Community believe in TAK or GMAB?

Genmab A/S received 45 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 61.18% of users gave Genmab A/S an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%
Genmab A/S	Outperform Votes 145 61.18%	Underperform Votes 92 38.82%

Do analysts rate TAK or GMAB?

Takeda Pharmaceutical currently has a consensus price target of $14.00, suggesting a potential upside of 3.93%. Genmab A/S has a consensus price target of $49.25, suggesting a potential upside of 77.35%. Given Takeda Pharmaceutical's higher possible upside, analysts clearly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Genmab A/S	3 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.38

Do insiders & institutionals have more ownership in TAK or GMAB?

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Is TAK or GMAB more profitable?

Genmab A/S has a net margin of 30.74% compared to Genmab A/S's net margin of 6.18%. Takeda Pharmaceutical's return on equity of 18.90% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	6.18%	9.92%	4.71%
Genmab A/S	30.74%	18.90%	16.83%

Summary

Genmab A/S beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.